IN2014MN02497A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02497A
IN2014MN02497A IN2497MUN2014A IN2014MN02497A IN 2014MN02497 A IN2014MN02497 A IN 2014MN02497A IN 2497MUN2014 A IN2497MUN2014 A IN 2497MUN2014A IN 2014MN02497 A IN2014MN02497 A IN 2014MN02497A
Authority
IN
India
Prior art keywords
acceptable salt
pharmacologically acceptable
inhibitory action
kinase enzyme
compound
Prior art date
Application number
Other languages
English (en)
Inventor
Yasuyuki Takeda
Kenji Yoshikawa
Yoshiko Kagoshima
Yuko Yamamoto
Ryoichi Tanaka
Yuichi Tominaga
Masaki Kiga
Yoshito Hamada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IN2014MN02497A publication Critical patent/IN2014MN02497A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2497MUN2014 2012-06-04 2013-06-03 IN2014MN02497A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体

Publications (1)

Publication Number Publication Date
IN2014MN02497A true IN2014MN02497A (es) 2015-07-17

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2497MUN2014 IN2014MN02497A (es) 2012-06-04 2013-06-03

Country Status (32)

Country Link
US (2) US9187489B2 (es)
EP (1) EP2857404B1 (es)
JP (1) JP5814467B2 (es)
KR (1) KR101781255B1 (es)
CN (1) CN104520300B (es)
AU (1) AU2013272701B2 (es)
BR (1) BR112014029851B1 (es)
CA (1) CA2874819C (es)
CO (1) CO7160119A2 (es)
CY (1) CY1119607T1 (es)
DK (1) DK2857404T3 (es)
ES (1) ES2648228T3 (es)
HK (1) HK1207374A1 (es)
HR (1) HRP20171724T1 (es)
HU (1) HUE037221T2 (es)
IL (1) IL236075A (es)
IN (1) IN2014MN02497A (es)
LT (1) LT2857404T (es)
MX (1) MX357021B (es)
MY (1) MY170326A (es)
NO (1) NO2857404T3 (es)
NZ (1) NZ702574A (es)
PH (1) PH12014502721B1 (es)
PL (1) PL2857404T3 (es)
PT (1) PT2857404T (es)
RS (1) RS56625B1 (es)
RU (1) RU2635917C2 (es)
SG (1) SG11201408052WA (es)
SI (1) SI2857404T1 (es)
TW (1) TWI585088B (es)
WO (1) WO2013183578A1 (es)
ZA (1) ZA201408843B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
RS62869B1 (sr) 2008-10-22 2022-02-28 Array Biopharma Inc Substituisana jedinjenja pirazolo[1,5-a]pirimidina kao inhibitori trk kinaze
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2534335T3 (es) 2010-05-20 2015-04-21 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la Trk cinasa
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
EA032255B1 (ru) 2014-03-27 2019-04-30 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-a][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Ros1
ES2686747T3 (es) * 2014-03-27 2018-10-19 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y derivados de 2,3-dihidro-1H-imidazo[1,2-b]pirazol sustituidos como inhibidores de ROS1
AU2015249232B2 (en) * 2014-04-25 2020-06-25 Exelixis, Inc. Method of treating lung adenocarcinoma
HRP20230271T1 (hr) 2014-11-16 2023-06-09 Array Biopharma, Inc. Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogen sulfata
US20180140604A1 (en) 2015-06-01 2018-05-24 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
CA3014432C (en) 2015-06-18 2024-05-07 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
KR20180026459A (ko) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
KR102400423B1 (ko) 2016-04-04 2022-05-19 록쏘 온콜로지, 인코포레이티드 (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-하이드록시피롤리딘-1-카복사미드의 액체 제형
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
SG11201808676RA (en) 2016-04-04 2018-11-29 Loxo Oncology Inc Methods of treating pediatric cancers
PE20190437A1 (es) 2016-05-18 2019-03-27 Loxo Oncology Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
AU2018234027B2 (en) * 2017-03-14 2021-12-09 Daiichi Sankyo Company, Limited Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
WO2019107671A1 (ko) * 2017-11-29 2019-06-06 서울대학교 산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN113194928A (zh) 2018-07-31 2021-07-30 罗索肿瘤学公司 (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
US20220185815A1 (en) * 2019-03-06 2022-06-16 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220007111A (ko) * 2019-05-08 2022-01-18 티와이케이 메디슨즈, 인코포레이티드 키나아제 억제제로 사용되는 화합물 및 이의 응용
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
AU2021453749A1 (en) * 2021-07-01 2023-12-21 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds
CN114989176A (zh) * 2022-07-08 2022-09-02 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115A (zh) * 2022-08-25 2022-10-18 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US6964977B2 (en) 2000-09-01 2005-11-15 Smithkline Beecham Corporation Oxindole derivatives
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20090227648A1 (en) 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
WO2006087538A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
EP1912987A1 (en) * 2005-08-01 2008-04-23 F. Hoffmann-Roche AG Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
CA2667962A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
SG176461A1 (en) * 2006-11-06 2011-12-29 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
US8507488B2 (en) 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
CY1119607T1 (el) 2018-04-04
TW201400486A (zh) 2014-01-01
IL236075A (en) 2017-10-31
ES2648228T3 (es) 2017-12-29
NO2857404T3 (es) 2018-01-20
PL2857404T3 (pl) 2018-04-30
CA2874819C (en) 2017-06-20
RU2014153627A (ru) 2016-08-10
JP5814467B2 (ja) 2015-11-17
US9187489B2 (en) 2015-11-17
HUE037221T2 (hu) 2018-08-28
CO7160119A2 (es) 2015-01-15
BR112014029851B1 (pt) 2023-01-03
US20160046639A1 (en) 2016-02-18
SG11201408052WA (en) 2015-01-29
MX2014014803A (es) 2015-02-12
NZ702574A (en) 2016-07-29
AU2013272701B2 (en) 2017-12-21
EP2857404B1 (en) 2017-08-23
CN104520300A (zh) 2015-04-15
MY170326A (en) 2019-07-17
LT2857404T (lt) 2017-11-10
ZA201408843B (en) 2016-01-27
PT2857404T (pt) 2017-11-23
SI2857404T1 (sl) 2017-11-30
MX357021B (es) 2018-06-25
BR112014029851A2 (pt) 2017-06-27
DK2857404T3 (en) 2017-12-04
TWI585088B (zh) 2017-06-01
AU2013272701A1 (en) 2015-01-15
US20150051190A1 (en) 2015-02-19
KR20150014942A (ko) 2015-02-09
RS56625B1 (sr) 2018-03-30
JPWO2013183578A1 (ja) 2016-01-28
US9751887B2 (en) 2017-09-05
HK1207374A1 (en) 2016-01-29
WO2013183578A1 (ja) 2013-12-12
EP2857404A1 (en) 2015-04-08
PH12014502721A1 (en) 2015-02-02
EP2857404A4 (en) 2016-01-20
RU2635917C2 (ru) 2017-11-17
HRP20171724T1 (hr) 2018-01-12
KR101781255B1 (ko) 2017-09-22
IL236075A0 (en) 2015-02-01
PH12014502721B1 (en) 2015-02-02
CA2874819A1 (en) 2013-12-12
AU2013272701A2 (en) 2015-01-22
CN104520300B (zh) 2016-12-21

Similar Documents

Publication Publication Date Title
IN2014MN02497A (es)
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
PH12016501813B1 (en) 1,3-benzodioxole derivative
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
CA2871471C (en) Dna-pk inhibitors
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
EA027213B9 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
GEP201606555B (en) Compounds and compositions for modulating egfr activity
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
MY172924A (en) Neprilysin inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201491456A1 (ru) Соединения-ингибиторы raf
MX2013009873A (es) Inhibidores triciclicos de cinasas.
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
WO2013004995A8 (en) Pyrimidinone compounds and their use
WO2013040227A3 (en) Therapeutic compounds
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
MX340574B (es) Imidazo pirazinas.
PH12015501146A1 (en) Hydantoin derivative
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor